Parkinson's Disease Clinical Trial
Official title:
BradyXplore Phase II: Bradykinesia Feature Extraction System
Study objectives are to improve motion sensor algorithms for measuring bradykinesia in the clinic and the home, evaluate test-retest reliability of motion sensor algorithms for measuring bradykinesia compared to clinician raters, determine if participant-perceived symptom severities correlate with motion sensor measures, determine if speed, amplitude, and rhythm fluctuate differentially throughout the day in individuals with implanted deep brain stimulation systems, and receive feedback on the usability of Kinesia One.
In Clinic:
Participants will arrive at the clinic with deep brain stimulation (DBS) turned on and on
any previously prescribed Parkinson's disease (PD) medication. Motion sensor units will be
placed on the index finger, thumb, and wrist of the participant's more affected hand. The
participant will then perform three repetitive motion tasks and two tremor evaluation tasks,
each performed for 15 seconds. The tasks will include repetitive finger-tapping, hand
opening-closing, and pronation-supination, as well as arms resting and arms extended. The
sequence of five tasks will be repeated (10 task performances total) so that test-retest
reliability can be examined.
The participant's DBS system will then be turned off. The two repetitions of five motor
tasks will then be repeated 10 minutes, 20 minutes, and 30 minutes after DBS is turned off
to measure the after-effects of DBS washout. During all task performances, motion data will
be streamed from the motion sensors to a nearby computer for storage. The participant's hand
will be videoed for subsequent clinical scoring. After each set of assessments (on and three
time points after turning DBS off), participants will be asked to rate his/her "slowness of
movement" on a 0-4 scale. The participant's DBS system will then be turned back on before
he/she leaves the clinic.
To examine test-retest reliability, motion sensor-based scores will be compared to the
clinician ratings. Videos from participants at both sites will be randomized, and presented
to movement disorder neurologists for clinical rating. The clinician will be blinded to the
participant's identity as much as possible by obscuring everything other than the
participant's hand.
At Home:
Before data collection begins, a technician will give the participant a Kinesia One system
(one motion sensor unit, inductive charge-pad, and tablet computer) to take home and train
him/her on use. The movement tasks to be performed will be explained in detail to ensure the
participant is familiar with them. The participant will be required to perform the tasks
using the system twice independently before leaving the clinic to ensure he/she fully
understands how to use the system. The time it takes the participant to independently set up
the system will be recorded. The system will be used for two weeks, after which it will be
returned to the clinic either in person or in a pre-paid shipping box.
During the two-week data collection, participants will perform a motor assessment three days
per week (six days total). On each assessment day, assessments will be performed six times
per day, spaced approximately two hours apart. All assessments will be performed with DBS
turned ON. To begin each assessment, the participant will sit in front of the tablet
computer. The software will guide the participant through the data collection procedure. The
participant will be instructed to remove the motion sensor unit from the charge pad and
place it appropriately on the index finger of the more affected hand. Software will then
guide the participant through the assessment, which will consist of the three repetitive
motion tasks and two tremor evaluation tasks, each performed for 15 seconds. The sequence of
five tasks will be repeated a second time (10 task performances total) so that test-retest
reliability can be examined. All data will be uploaded to a secure server. After each
assessment, participants will enter rating corresponding to their perceived slowness of
movement and Parkinson's state. Each week of paper diaries will be mailed back within three
days after being completed in provided, pre-addressed and stamped envelopes.
;
Observational Model: Cohort, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02915848 -
Long-term Stability of LFP Recorded From the STN and the Effects of DBS
|
||
Recruiting |
NCT03648905 -
Clinical Laboratory Evaluation of Chronic Autonomic Failure
|
||
Terminated |
NCT02688465 -
Effect of an Apomorphine Pump on the Quality of Sleep in Parkinson's Disease Patients (POMPRENELLE).
|
Phase 4 | |
Completed |
NCT05040048 -
Taxonomy of Neurodegenerative Diseases : Observational Study in Alzheimer's Disease and Parkinson's Disease
|
||
Active, not recruiting |
NCT04006210 -
Efficacy, Safety and Tolerability Study of ND0612 vs. Oral Immediate Release Levodopa/Carbidopa (IR-LD/CD) in Subjects With Parkinson's Disease Experiencing Motor Fluctuations
|
Phase 3 | |
Completed |
NCT02562768 -
A Study of LY3154207 in Healthy Participants and Participants With Parkinson's Disease
|
Phase 1 | |
Completed |
NCT00105521 -
Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia
|
Phase 3 | |
Completed |
NCT00105508 -
Sarizotan HC1 in Patients With Parkinson's Disease Suffering From Treatment-associated Dyskinesia
|
Phase 3 | |
Recruiting |
NCT06002581 -
Repetitive Transcranial Magnetic Stimulation(rTMS) Regulating Slow-wave to Delay the Progression of Parkinson's Disease
|
N/A | |
Completed |
NCT02236260 -
Evaluation of the Benefit Provided by Acupuncture During a Surgery of Deep Brain Stimulation
|
N/A | |
Completed |
NCT00529724 -
Body Weight Gain, Parkinson, Subthalamic Stimulation
|
Phase 2 | |
Active, not recruiting |
NCT05699460 -
Pre-Gene Therapy Study in Parkinson's Disease and Multiple System Atrophy
|
||
Completed |
NCT03703570 -
A Study of KW-6356 in Patients With Parkinson's Disease on Treatment With Levodopa-containing Preparations
|
Phase 2 | |
Completed |
NCT03462680 -
GPR109A and Parkinson's Disease: Role of Niacin in Outcome Measures
|
N/A | |
Completed |
NCT02837172 -
Diagnosis of PD and PD Progression Using DWI
|
||
Not yet recruiting |
NCT04046276 -
Intensity of Aerobic Training and Neuroprotection in Parkinson's Disease
|
N/A | |
Recruiting |
NCT02952391 -
Assessing Cholinergic Innervation in Parkinson's Disease Using the PET Imaging Marker [18F]Fluoroethoxybenzovesamicol
|
N/A | |
Active, not recruiting |
NCT02937324 -
The CloudUPDRS Smartphone Software in Parkinson's Study.
|
N/A | |
Completed |
NCT02927691 -
Novel Management of Airway Protection in Parkinson's Disease: A Clinical Trial
|
Phase 2 | |
Terminated |
NCT02924194 -
Deep Brain Stimulation of the nbM to Treat Mild Cognitive Impairment in Parkinson's Disease
|
N/A |